Skip to content
Sign in

XPH · ARCA · ETF

State Street SPDR S&P Pharmaceuticals ETF (XPH) Price, Holdings & Fees

$297.43−1.24%−$3.73End-of-day price as of Oct 9, 2026

State Street SPDR S&P Pharmaceuticals ETF (XPH) closed at $297.43 on Oct 9, 2026, down 1.24% from the previous close of $301.16.

Share price, past year

1Y −6.05%

52-week range $293.09 – $354.07. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$297.43
Sep 30, 2026$294.12
Aug 31, 2026$296.59
Jul 31, 2026$312.48
Jun 30, 2026$302.44
May 29, 2026$311.97
Apr 30, 2026$320.59
Mar 31, 2026$340.15
Feb 27, 2026$338.43
Jan 30, 2026$350.79
Dec 31, 2025$341.88
Nov 28, 2025$329.45
Oct 31, 2025$324.63

Key statistics

Expense ratio
0.35%
as of Jun 30, 2025
Net assets
$428.4M
as of Jun 30, 2026
Holdings
67
as of Jun 30, 2026
52-week range
$293.09 – $354.07

State Street SPDR S&P Pharmaceuticals ETF's expense ratio is 0.35%: $35.00 a year on $10,000 invested.

Holdings

State Street SPDR S&P Pharmaceuticals ETF held 67 investments worth $428.43M as of Jun 30, 2026. Its largest holding was State Street Global Advisors, at 8.58% of the fund.

State Street SPDR S&P Pharmaceuticals ETF largest holdings by share of net assets
#Holding% of fundValue
1State Street Global Advisors8.58%$36.75M
2Definium Therapeutics Inc3.09%$13.23M
3MBX Biosciences Inc2.72%$11.65M
4Alumis Inc2.14%$9.17M
5AtaiBeckley Inc2.13%$9.11M
6Trevi Therapeutics Inc2.12%$9.10M
7Enliven Therapeutics Inc2.09%$8.97M
8Amylyx Pharmaceuticals Inc2.04%$8.72M
9VeraDermics Inc2.02%$8.64M
10Ligand Pharmaceuticals Inc1.94%$8.32M
11Nuvation Bio Inc1.89%$8.11M
12Edgewise Therapeutics Inc1.88%$8.07M
13Nektar Therapeutics1.88%$8.04M
14Liquidia Corp1.86%$7.99M
15Maze Therapeutics Inc1.85%$7.93M
16Harrow Inc1.81%$7.73M
17EyePoint Inc1.77%$7.58M
18Amneal Pharmaceuticals Inc1.72%$7.39M
19Ocular Therapeutix Inc1.71%$7.35M
20Corcept Therapeutics Inc1.70%$7.28M
21Crinetics Pharmaceuticals Inc1.66%$7.13M
22Pacira BioSciences Inc1.65%$7.08M
23Merck & Co Inc1.65%$7.05M
24Indivior Pharmaceuticals Inc1.64%$7.04M
25Elanco Animal Health Inc1.64%$7.04M

Top 25 of 67 holdings, as of Jun 30, 2026. Percentages are of the fund's net assets.

What the fund owns

State Street SPDR S&P Pharmaceuticals ETF holdings by asset type
Asset type% of fund
Stocks99.95%
Cash and short-term investments8.64%
State Street SPDR S&P Pharmaceuticals ETF holdings by country, largest 6
Country% of fund
United States98.39%
Canada3.09%
Ireland3.02%
United Kingdom1.57%
Singapore1.57%
Cayman Islands0.96%

Shares of net assets from the fund's N-PORT report. Funds that borrow can add up to more than 100%, with borrowing (such as repurchase agreements) shown as a negative share.

Monthly total returns

Over the 3 months to Jun 30, 2026, State Street SPDR S&P Pharmaceuticals ETF's total return was +23.09%, as reported to the SEC.

State Street SPDR S&P Pharmaceuticals ETF monthly total returns
MonthTotal return
Jun 30, 2026+13.98%
May 31, 2026+1.09%
Apr 30, 2026+6.83%

The fund's own total returns as reported to the SEC (N-PORT), including reinvested distributions. Not the sample prices above.

Fund profile

Name
State Street SPDR S&P Pharmaceuticals ETF
Ticker
XPH
Exchange
ARCA
Fund type
ETF
Trust
SPDR SERIES TRUST
SEC series ID
S000012321
SEC CIK
0001064642
Fractional shares
Yes

Recent SEC filings

Shareholder reports and prospectuses are filed by SPDR SERIES TRUST, the trust behind State Street SPDR S&P Pharmaceuticals ETF, and cover all of its funds.

Frequently asked questions

What is XPH's price?

State Street SPDR S&P Pharmaceuticals ETF (XPH) closed at $297.43 on Oct 9, 2026, down 1.24% from the previous close of $301.16.

What is XPH's expense ratio?

State Street SPDR S&P Pharmaceuticals ETF's expense ratio is 0.35%: $35.00 a year on $10,000 invested.

What does XPH hold?

State Street SPDR S&P Pharmaceuticals ETF held 67 investments worth $428.43M as of Jun 30, 2026. Its largest holding was State Street Global Advisors, at 8.58% of the fund. Its five largest holdings were State Street Global Advisors, Definium Therapeutics Inc, MBX Biosciences Inc, Alumis Inc, AtaiBeckley Inc.

How has XPH performed?

Over the 3 months to Jun 30, 2026, State Street SPDR S&P Pharmaceuticals ETF's total return was +23.09%, as reported to the SEC.

Sources and methodology

Holdings, net assets and monthly returns come from the fund's N-PORT filing with the SEC, as of Jun 30, 2026 (filed Aug 28, 2026). The expense ratio is from the fund's prospectus or shareholder report, as of Jun 30, 2025. Prices are generated sample data for development. Data sources and disclosures